You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

621 Results
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Intent: Curative
Funding:
ODB - General Benefit
    mercaptopurine
ODB - General Benefit
    prednisone
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), according to specific clinical criteria
Mar 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL), 
Leukemia - Acute Myeloid (AML), 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative, Curative
Jan 2018
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Curative
Funding:
ODB - General Benefit
    megestrol - oral tablets
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Curative
Funding:
ODB - General Benefit
  • medroxyprogesterone
Oct 2017
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) - As Part of the MATRix Regimen in Newly Diagnosed Previously Untreated PCNSL
Jan 2023
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant
ODB - General Benefit
    dexamethasone
ODB - General Benefit
    cyclophosphamide - oral tablets
Sep 2019
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Liposomal Doxorubicin - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer
New Drug Funding Program
    Bevacizumab (Biosimilar) for Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The questions on Your Voice Matters ask you how you feel about your most recent cancer care appointment. You can tell us about an in-person (at the...
Document
Document

Pages